Adhera Therapeutics Past Earnings Performance
Past criteria checks 0/6
Adhera Therapeutics's earnings have been declining at an average annual rate of -4.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-4.8%
Earnings growth rate
48.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Adhera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -5 | 1 | 0 |
| 30 Jun 23 | 0 | -3 | 2 | 0 |
| 31 Mar 23 | 0 | -3 | 2 | 0 |
| 31 Dec 22 | 0 | -3 | 2 | 0 |
| 30 Sep 22 | 0 | -4 | 1 | 0 |
| 30 Jun 22 | 0 | -7 | 1 | 0 |
| 31 Mar 22 | 0 | -8 | 1 | 0 |
| 31 Dec 21 | 0 | -8 | 1 | 0 |
| 30 Sep 21 | 0 | -7 | 1 | 0 |
| 30 Jun 21 | 0 | -4 | 1 | 0 |
| 31 Mar 21 | 0 | -4 | 1 | 0 |
| 31 Dec 20 | 0 | -5 | 2 | 0 |
| 30 Sep 20 | 0 | -9 | 5 | 0 |
| 30 Jun 20 | 0 | -11 | 6 | 0 |
| 31 Mar 20 | 0 | -13 | 9 | 0 |
| 31 Dec 19 | 0 | -13 | 10 | 0 |
| 30 Sep 19 | 0 | -12 | 10 | 0 |
| 30 Jun 19 | 0 | -18 | 10 | 0 |
| 31 Mar 19 | 0 | -19 | 11 | 0 |
| 31 Dec 18 | 0 | -18 | 10 | 0 |
| 30 Sep 18 | 0 | -17 | 10 | 0 |
| 30 Jun 18 | 0 | -10 | 8 | 1 |
| 31 Mar 18 | 0 | -6 | 5 | 1 |
| 31 Dec 17 | 0 | -6 | 5 | 1 |
| 30 Sep 17 | 0 | -4 | 2 | 1 |
| 30 Jun 17 | 0 | -3 | 2 | 1 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 0 | 0 |
Quality Earnings: ATRX is currently unprofitable.
Growing Profit Margin: ATRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ATRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ATRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ATRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.